If you liked this article you might like

PTC Therapeutics Getting Cold Shoulder From Regulators on Duchenne Drug Appeal
Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics
New Setback for Sanofi's Lantus Increases Need for M&A
Biotech Stock Mailbag: Sarepta Therapeutics Approval Edition